CoChat

Evaluation of clinical benefits of treatments for Alzheimer's disease

Open access

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Abstract

The need for regulatory approval of new therapies for the treatment of Alzheimer's disease-a progressive neurodegenerative condition-has made the assessment of treatment efficacy an urgent priority for discussion and investigation in the field. In the first part of this Personal View, we summarise current views on what constitutes a clinically meaningful benefit from treatment for Alzheimer's disease, including the concept of a minimum treatment effect against which to compare trial outcomes and its limitations. Considering existing and divergent definitions of clinically meaningful change, we define this concept in the second part of the Personal View by proposing a new approach that consecutively considers whether a treatment benefit for Alzheimer's disease is noticeable, valuable, and worthwhile in the context of costs and risks. This approach could be a useful foundation from which the field can move forwards on this issue and address existing gaps in understanding.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2666-7568(23)00193-9

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

See all 31

Metadata

Authors
Liu, K. Y., Walsh, S., Brayne, C., Merrick, R., Richard, E., & Howard, R.
Affiliations
  • University College London (GB)
  • University of Cambridge (GB)
  • Radboud University Nijmegen (NL)
Corresponding author
Liu, Kathy Y
Venue
The Lancet Healthy Longevity
Publisher
Elsevier BV
Published
2023-11
Volume
4
Issue
11
Pages
e645-e651
ISSN
2666-7568 (ISSN-L)
OpenAlex
W4388164740
Cited by
31
References
39
Citations by year
2026: 6 · 2025: 12 · 2024: 12 · 2023: 1
FWCI
1.10
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Healthy Longevity (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (acceptedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • Radboud Repository (Radboud University) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion, cc-by)
Funders
  • Alzheimer’s Research UK (ARUK-PhD2017–34)
  • Medical Research Council (MR/S021418/1)
  • National Institute for Health and Care Research
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
Alzheimer's disease, treatment efficacy, regulatory approval, clinical trial results, cost-effectiveness, risk-benefit assessment, neurodegenerative diseases
MeSH terms
Alzheimer Disease, Humans, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of clinical benefits of treatments for Alzheimer's disease. https://app.cochat.ai/papers/10.1016/s2666-7568(23)00193-9
The paper
Liu, K. Y., Walsh, S., Brayne, C., Merrick, R., Richard, E., & Howard, R. (2023). Evaluation of clinical benefits of treatments for Alzheimer's disease. The Lancet Healthy Longevity. https://doi.org/10.1016/s2666-7568(23)00193-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.